===AIB Data Centers (AIB) : 5-month performance

 

BlockchAIn Digital Infrastructure became a publicly traded company on the NYSE American under the ticker AIB on March 16, 2026, following a business combination rather than a traditional initial public offering (IPO). 

 

Listing Date: March 16, 2026

Previous Name: BlockchAIn Digital Infrastructure, Inc.

Name Change: Switched to AIB Data Centers Inc. in June 2026.

Exchange / Ticker: NYSE American: AIB

Transaction Type: Business combination (succeeding Signing Day Sports, Inc.)

Strategic Focus: Transitioning operations from Bitcoin mining to high-performance computing (HPC) and artificial intelligence (AI) data center hosting.

Website https://www.aib.us/

Business Strategy

Power-First Model: Focuses on securing utility capacity and energy services agreements before starting development.
Asset Conversion: Converts powered land and legacy crypto-mining infrastructure into high-density, AI-ready data center capacity.
Operations: Provides modular electrical and facility hosting systems while tenants supply their own hardware and GPUs. 

 

 Celebrated its corporate rebrand and public listing by ringing the NYSE Opening Bell on July 10, 2026

 

 

Signing Day Sports went public on November 14, 2023, raising $6 million by offering 1.2 million shares at $5.00 per share on the NYSE American under the ticker symbol SGN. The student-athlete recruiting platform later combined with BlockchAIn Digital Infrastructure in March 2026

 

IPO Date: November 14, 2023

Offer Size: Raised $6 million (1.2 million shares at $5.00 each)

Exchange / Ticker: NYSE American under SGN

Underwriter: Boustead Securities

IPO and Post-IPO Timeline

Initial Filing: First submitted paperwork to the SEC in 2023 with multiple downsized terms before finalizing.
Offering Details: Offered 1.2 million shares at $5.00 to raise $6 million with Boustead Securities as the sole bookrunner.
Subsequent Capital & Merger: Executed additional public offerings (such as a $5.6 million offering in early 2026) and subsequently moved forward with a business combination with BlockchAIn Digital Infrastructure approved in March 2026

==StableCoinX (USDE) : 2-month performance,

StablecoinX Inc., a stablecoin infrastructure company, focuses on the Ethena digital dollar ecosystem. It offers infrastructure services, stablecoin middleware software, and stablecoin distribution services. The company is based in Frisco, Texas.

Sector: Financial Services

Industry: Capital Markets

https://stablecoinx.com

StablecoinX completed its public market debut on June 26, 2026, via a business combination with the special purpose acquisition company (SPAC) TLGY Acquisition Corp. Its Class A common stock trades on Nasdaq under the ticker symbol USDE. 

Public Listing Details

Transaction Date: June 26, 2026 (following the closure of the merger with TLGY Acquisition Corp. on June 25, 2026).
Exchange / Ticker: Nasdaq Capital Market under USDE (Class A shares) and USDEW (warrants).
Core Focus: Functioning as a public stablecoin infrastructure firm and treasury vehicle centered around the Ethena Labs ecosystem, holding a multi-year treasury strategy in ENA governance tokens.
Leadership: Led by CEO Edward Chen

Apnimed (APMD) began trading on the Nasdaq on Fri 31 Jul 26

Sector: Pharmaceutical industry
Employees 65

Founded by Lawrence G. Miller, Barry Wohl and Luigi Taranto Montemurro in 2017 

Headquartered in Cambridge, MA
Website apnimed.com
Apnimed opened at $22 after pricing IPO at $16/share 

 

• Apnimed (APMD) is off to a successful public-market debut, with its upsized 12.0 mln share IPO pricing at $16 -- the top of its $14--$16 range -- before opening at $22 for a 38% gain, signaling strong investor demand for the late-stage sleep-medicine developer.
• The biopharmaceutical company is developing oral therapies for sleep-related breathing disorders, led by Oxnimbi, also known as AD109, a once-nightly combination drug designed to improve upper-airway muscle activity and prevent airway collapse in patients with obstructive sleep apnea.
• APMD's primary end market is the large OSA population, where current treatment is dominated by devices such as CPAP, giving a convenient oral therapy the potential to expand diagnosis, treatment adoption, and patient compliance if approved.
• The company submitted an NDA for Oxnimbi in April 2026 following positive Phase 3 trials, and the FDA accepted the application for review in July, making regulatory approval and commercialization the central near-term catalysts for the story.
• For the three months ended March 31, 2026, APMD reported $84.8 mln of related-party revenue, up sharply from $3.1 mln a year earlier, while income from operations swung to $68.0 mln from a $27.1 mln loss.
• That financial improvement should be viewed cautiously, however, because the revenue was tied primarily to licensing, know-how, and research-service arrangements with its SASS joint venture rather than recurring commercial product sales, meaning the IPO's longer-term success will ultimately depend on Oxnimbi's approval, launch execution, reimbursement, and physician and patient adoption.